Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway.
Angela SamyMohamed Ali HusseinGnanasekar MunirathinamPublished in: Journal of cancer research and clinical oncology (2023)
Our study shows that EP has tremendous potential to target metastatic PCa cells and provides new avenues for therapeutic approaches for advanced PCa.